Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Jenkintown, PA
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Jenkintown, PA
Click here to add this to my saved trials
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Warwick, RI
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Warwick, RI
Click here to add this to my saved trials
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Bluffton, SC
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Bluffton, SC
Click here to add this to my saved trials
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Bristol, TN
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Bristol, TN
Click here to add this to my saved trials
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Dallas, TX
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Salt Lake City, UT
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Norfolk, VA
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Seattle, WA
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Wauwatosa, WI
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 11/21/2013
Warner Chilcott Investigational Study Site
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects With Ocular Redness.
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Adult and Geriatric Subjects With Ocular Redness
Status: Enrolling
Updated:  11/27/2013
Bausch & Lomb Incorporated
mi
from
Madison, NJ
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects With Ocular Redness.
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Adult and Geriatric Subjects With Ocular Redness
Status: Enrolling
Updated: 11/27/2013
Bausch & Lomb Incorporated
mi
from
Madison, NJ
Click here to add this to my saved trials
Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
Phase 1 Study of Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
Status: Enrolling
Updated:  12/3/2013
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
Phase 1 Study of Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
Status: Enrolling
Updated: 12/3/2013
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients
Status: Enrolling
Updated:  12/10/2013
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients
Status: Enrolling
Updated: 12/10/2013
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated:  12/13/2013
University of California at San Diego
mi
from
San Diego, CA
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated: 12/13/2013
University of California at San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated:  12/13/2013
Washington University
mi
from
St. Louis, MO
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated: 12/13/2013
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.
Immunological Changes in Chronic Graft Versus Host Disease Treated With Extracorporeal Photopheresis
Status: Enrolling
Updated:  12/30/2013
Children's Mercy Hospital
mi
from
Kansas City, MO
Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.
Immunological Changes in Chronic Graft Versus Host Disease Treated With Extracorporeal Photopheresis
Status: Enrolling
Updated: 12/30/2013
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.
Immunological Changes in Chronic Graft Versus Host Disease Treated With Extracorporeal Photopheresis
Status: Enrolling
Updated:  12/30/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.
Immunological Changes in Chronic Graft Versus Host Disease Treated With Extracorporeal Photopheresis
Status: Enrolling
Updated: 12/30/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease
A Study of Extracorporeal Photopheresis With UVADEX® in the Setting of a Standard Myeloablative Conditioning Regimen in Related or Unrelated Donor Hematopoietic Stem Cell Transplantation for the Prevention of Graft Versus Host Disease
Status: Enrolling
Updated:  12/30/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease
A Study of Extracorporeal Photopheresis With UVADEX® in the Setting of a Standard Myeloablative Conditioning Regimen in Related or Unrelated Donor Hematopoietic Stem Cell Transplantation for the Prevention of Graft Versus Host Disease
Status: Enrolling
Updated: 12/30/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Status: Enrolling
Updated:  1/3/2014
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Status: Enrolling
Updated: 1/3/2014
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
An Open Label Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  1/3/2014
Arkansas Children's Hospital
mi
from
Little Rock, AR
Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
An Open Label Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 1/3/2014
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
An Open Label Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  1/3/2014
Long Island Jewish Medical Center - Hemophilia Treatment Center
mi
from
New Hyde Park, NY
Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
An Open Label Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 1/3/2014
Long Island Jewish Medical Center - Hemophilia Treatment Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% in a Population of Pediatric, Adult, and Geriatric Subjects.
Status: Enrolling
Updated:  1/12/2014
Bausch & Lomb Incorporated
mi
from
Madison, NJ
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% in a Population of Pediatric, Adult, and Geriatric Subjects.
Status: Enrolling
Updated: 1/12/2014
Bausch & Lomb Incorporated
mi
from
Madison, NJ
Click here to add this to my saved trials
Imaging Studies and the Development of Multiple Myeloma
Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease
Status: Enrolling
Updated:  1/14/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Imaging Studies and the Development of Multiple Myeloma
Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease
Status: Enrolling
Updated: 1/14/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Status: Enrolling
Updated:  1/14/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Status: Enrolling
Updated: 1/14/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase I Study of Milatuzumab for Graft Versus Host Disease
A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  1/22/2014
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Phase I Study of Milatuzumab for Graft Versus Host Disease
A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 1/22/2014
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
UCLA Division of Hematology-Oncology
mi
from
Los Angeles, CA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
UCLA Division of Hematology-Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
Mayo Clinic
mi
from
Jacksonville, FL
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
University of Kansas Cancer Center and Medical Center
mi
from
Westwood, KA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
University of Kansas Cancer Center and Medical Center
mi
from
Westwood, KA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
B. Douglas Smith, M.D.
mi
from
Baltimore, MD
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
B. Douglas Smith, M.D.
mi
from
Baltimore, MD
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
Dana-Farber Cancer Inst
mi
from
Boston, MA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
Dana-Farber Cancer Inst
mi
from
Boston, MA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
Dana-Farber Cancer Inst
mi
from
Boston, MA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
Dana-Farber Cancer Inst
mi
from
Boston, MA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
University of Washington School of Medicine
mi
from
Seattle, WA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
University of Washington School of Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B
Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B
Status: Enrolling
Updated:  1/27/2014
Clinical Research Facility
mi
from
Chicago, IL
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B
Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B
Status: Enrolling
Updated: 1/27/2014
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Immunoablative Protocol for Allogeneic Related and Unrelated Hematopoietic Peripheral Blood Stem Cell Transplant (HPBSC)
Status: Enrolling
Updated:  1/30/2014
Children's Memorial Hospital
mi
from
Chicago, IL
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Immunoablative Protocol for Allogeneic Related and Unrelated Hematopoietic Peripheral Blood Stem Cell Transplant (HPBSC)
Status: Enrolling
Updated: 1/30/2014
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Children's Hospital of Orange County
mi
from
Orange, CA
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
UCSF School of Medicine
mi
from
San Francisco, CA
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
UCSF School of Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Childrens National Medical Center
mi
from
Washington,
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
University of Miami Cancer Center
mi
from
Miami, FL
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
University of Miami Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Lurie Children's Hospital
mi
from
Chicago, IL
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Johns Hopkins University
mi
from
Baltimore, MD
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Dana Farber
mi
from
Boston, MA
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Dana Farber
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials